Brief: Vistagen Therapeutics Says PH80 Was Well-Tolerated With Adverse Event Profile Similar To Placebo
12/09/2023 14:46
Sept 12 (Reuters) - VistaGen Therapeutics Inc VTGN.O :
* VISTAGEN ANNOUNCES POSITIVE RESULTS FROM EXPLORATORY PHASE
2A
STUDY OF PH80 FOR ACUTE MANAGEMENT OF THE SYMPTOMS OF
PREMENSTRUAL DYSPHORIC DISORDER
* VISTAGEN THERAPEUTICS INC - PH80 WAS WELL-TOLERATED WITH
AN
ADVERSE EVENT PROFILE SIMILAR TO PLACEBO
Source text for Eikon: ID:nBw69qCxa
Further company coverage: VTGN.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Vistagen Therapeutics
See all newsBrief: Vistagen TherapeuticsSays Fasedienol Nasal Spray Well-Tolerated With No New Drug-Related Safety Findings After 12 Months
VistaGen Q1 revenue rises on licensing agreement expiration
Brief: VistaGen Q1 EPS USD -0.3
Vistagen Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Vistagen Appoints Douglas J. Williamson To Its Board Of Directors